Table of Contents Table of Contents
Previous Page  67 / 154 Next Page
Information
Show Menu
Previous Page 67 / 154 Next Page
Page Background

P001

RETROSPECTIVE STUDY EVALUATING THE EFFICACY AND

SAFETY OF FULVESTRANT AS FIRST OR SECOND LINE

TREATMENT OF METASTATIC BREAST CANCER PATIENTS

OVER 70 YEARS OF AGE

A. I. Jagiello-Gruszfeld

1,

*, I. Lemanska

1

, E. Szombara

1

,

E. Brewczynska

1

, A. Gorniak

1

, A. Majstrak-Hulewska

1

,

Z. Nowecki

1

1

Breast Cancer and Reconstructive Surgery Dept, Memorial Cancer

Center and Institute, Warsaw, Poland

Introduction:

Retrospective study evaluating the efficacy

and safety of fulvestrant as first or second line treatment of

metastatic breast cancer patients over 70 years of age.

Objectives:

We therefore performed a retrospective study

to evaluate the efficacy and toxicity profiles of fulvestrant in

ER pos breast cancer patients

70 years old, treated in first or

second line of therapy.

Methods:

We evaluated 68 consecutive, ER pos, breast

cancer patients over 70 years of age, who are treated at

our Clinic from 01 Mar. 2014 to 01 Jan. 2016. Treatment

was continued to progression or unaccepted toxicity. The

effectiveness of treatment with fulwestrant was assessed

as achieving CBR (CR + PR + SD

24 weeks). All patients were

evaluated for toxicity.

Results:

36 pts received fulvestrant as 1-st line treatment

(53%), and 32 as second line (47%) The majority of patients had

only a bone or bones and soft tissue metastases (62%). The

mean of age was 76.2 (range: 70–93). The majority of pts (70%)

previously received tamoxifen as adjuvant setting. 3 pts (5%)

received AI, and 17 (25%) tamoxifen and AI during adjuvant

therapy. Nausea grade 1, was observed in 2 pts (3%), In 12 pts

(18%) hot flushes in grade 2 was noted. Injection site reaction

grade 2 was reported in 1 pts (1.5%). CBR was reported in 58

patients (85%), 32 pts treated as first line and 26 as second line

of hormonal treatment.

Conclusion:

The results of our study suggest that fulvestrant

is an effective and safe as the hormonal treatment in the elderly.

Disclosure of interest:

None declared

Keywords:

Breast cancer, fulvestrant, hormonal treatment

P002

PRACTICE MANAGEMENT FOR ELDERLY PATIENTS WITH

BREAST CANCER FROM IMPLICATIONS OF A SURVEY BY

THE JAPAN CLINICAL ONCOLOGY GROUP

A. Shimomura

1,

*, M. Sawaki

2

, K. Tamura

1

, T. Mizutani

3

, Y. Taki

2

,

F. Nagashima

4

, H. Iwata

2

1

Breast and Medical Oncology, National Cancer Center Hospital,

Tokyo,

2

Breast Oncology, Aichi Cancer Center Hospital, Nagoya,

3

JJCOG Data Center/Operations Office, Center for Research

Administration and Support, National Cancer Center,

4

Medical

Oncology, Kyorin University School of Medicine, Tokyo, Japan

Introduction:

In practical setting there is little information

about the patterns of care for elderly breast cancer patients,

and a standardized strategy has not been established.

Objectives:

To address the patterns of care for elderly

breast cancer patients by questionnaire survey.

Methods:

We collected questionnaires to investigate

practice elderly breast cancer patients among 38 institutions

in Japan on May 2015.The questionnaire was comprised of five

parts: (1) definition of “elderly” for each treatment (surgery,

radiation therapy and chemotherapy), (2) clinical standard

anti-HER2 therapy in each age, (3) recommended dose of

docetaxel in each age, (4) considerations about conducting

future clinical trials and (5) other information about geriatric

oncology concerning breast cancer.

Results:

All answers were obtained within May 2015.

The proportion the questionnaire response was 86.8%.

Eighty years old was the most frequent upper limited age to

perform surgery and radiation therapy, on the contrary, as for

chemotherapy many physicians think it is difficult for over

70-75 years old as an adjuvant therapy. For HER2 positive

metastatic breast cancer, 82% of physicians recommended

combination therapy of DTX, trastuzumab and pertuzumab

(HPD) for 65 to 70 years old as standard care, although

54% of physicians do not recommended HPD for 70 to

75 years old as a first-line standard preference. Majority of

physicians recommended the doses of 75 mg/m

2

DTX for both

65-70 years old (63%) and 70-75 years old (52%), but did not

for over 75 years old. Many physicians (73%) recommended

60 mg/m

2

DTX for over 75 years old as first attempt. Ninety-

seven percent of physicians agree if that comprehensive

J O U R N A L O F G E R I A T R I C O N C O L O G Y 7 / 6 S 1 ( 2 0 1 6 ) S 3 7 – S 1 2 3

Av a i l a b l e o n l i n e a t

www. s c i e n c e d i r e c t . c om

ScienceDirect

1879-4068/Published by Elsevier Ltd.

SIOG 2016 – Abstract Submission – Poster Presentations